Dr. Beck has contributed to the R&D of anticancer mAbs (dalotuzumab/IGF-1R with Merck, h224G11/cMet with Abbott, h515H7/CXCR4, h6F4/JAM-A), vaccines and peptides. He is inventor on 16 patents and author of more than 90 publications (editorials, features, research papers, invited reviews and...

Andy Lee is Senior Vice President and Head, Global Clinical Trial Operations (GCTO). In this role, Andy leads and manages GCTO, with particular focus on global, in-patient clinical trials, designed and executed to meet cost, speed and quality standards. Andy is also responsible for the design and...

With nearly 30 years’ experience in pharmaceutical portfolio management, Jenny has a proven track record covering all aspects of a product’s lifecycle, including from early R&D to loss of exclusivity. She is a skilled coach and authentic leader, dedicated to unlocking the potential in...

Agnete B. Fredriksen is Co-Founder, President and Chief Scientific Officer of Vaccibody AS. She holds a M.Sc., Ph.D from Institute of Immunology, University of Oslo, Rikshospitalet in Norway where she designed and developed the first Vaccibody vaccines. Agnete is one of the inventors of the...

Alan Smith, is currently the Executive Vice President Technical Operations at Bellicum Pharmaceuticals. He has broad experience in the cell therapy area with over 30 years working in various senior management roles in research and development, manufacturing and quality in cell and gene therapy...

Martin Schiestl obtained his PhD in chemistry with focus on analytical sciences at the University of Innsbruck/Austria in 1996. In the same year he started his work on Biosimilar medicines at Sandoz. He build up the analytical and pharmaceutical development departments for Sandoz'...

Sarah Carter has more than 20 years of industry experience. She is currently the Executive Director of Global Study Operations, where she is responsible for overseeing Site and Data Management aspects of Phase 1-4 clinical studies.She previously served as the Executive Director of Global Clinical...

Alexey Rak got his M.Sc in Biology and Genetics, and in Biochemistry. He then completed PhDs in Biochemistry and Biophysics working on protein biosynthesis machinery characterization. He did his PostDoc and then held a Group Leader position at Max-Planck Institute for Molecular Physiology in...

Stephen Nabarro has 15 years experience in oncology research and drug development. He completed a PhD in paediatric oncology at University College London, followed by a Postdoctoral Fellowship at the Medical Research Council Laboratory of Molecular Biology in Cambridge. In 2007 Steve joined Cancer...

Andreas is co-founded Anaveon in April 2018, and previously was the Director of Autoimmunity, Transplantation & Inflammation, Novartis Institutes of  Biomedical Research, Basel Big Pharma experience in the discovery and development of immunomodulating drugs (26 years) Extensive BD&L...

Professor Sarfaraz K. Niazi, Ph.D., FRSB, FPAMS, FACB, SI, Executive Chairman, Karyo Biologics and PharmSci, is a globally recognized pioneer of the pharmaceutical and biopharmaceutical industry, with 50+ books, 100+ research papers, 100+ patents, several approved CPs to FDA, dozens of crafted...

Dr. Anna Tafuri is Medical Director within the Bayer Translational Medicine Oncology She has been responsible for the clinical translation and design of the FiH trials evaluating the first two TTC compounds targeting solid tumors within the Bayer Targeted Alpha therapy platform, and is currently...

Dr. Marjorie Shapiro received her Ph.D. in immunology in 1987 from the University of Pennsylvania where she studied molecular mechanisms underlying antibody diversity.  Her current research continues towards understanding antibody repertoire development in natural and artificial systems and...

Jonathan trained as a doctor at Dundee University, before following a career as a histopathologist at Yeovil District Hospital, where he was instrumental in developing its research capabilities. In 2003 he became Medical Director for the Trust, before moving on to University Hospitals Bristol –...

Darko received his Ph.D. from University of Düsseldorf, Germany, where he worked on biophysical analysis of proteins.After a post-doc at the Research-Centre Jülich studying interactions and structure of proteins  he took a position in X-Ray Crystallography at the Bio-Centre Basel, Switzerland.In...

Laszlo Vasko has over 2 decades of experience leading information technology enabled change initiatives in pharmaceutical drug development.  He recently joined Janssen Pharmaceutical, as Senior Director Business Technology Leader for Clinical Development and Innovation.  Prior, Laszlo worked at...

Dr Delphine Courmier is a Health Economics Director at Amgen with the responsibility of the biosimilar portfolio in the HTA Center of Excellence as well as Global Health Economics for the oncology biosimilars.Delphine joins from Baxter where she was Global Market Access lead for 2 hospital products ...

Martin Mueller, Ph.D., Biotech Engineer, started his career at a Biotech startup in Berlin, before being a GLP study director at the globally acting CRO “RCC” (today: Harlan Labs). With this experience he joined Schering-Plough’s Biotech division for building up the Global GMP Labs. In 2012, Martin ...

Liping Jin, Data-Driven Recruitment Lead, Roche Innovation Center New York.Liping has been with Roche for 20 years in different functions. In last a few years, he has been leading and increasingly focus on the data-driven recruitment effort with clinical teams at Roche pRED. The service is designed ...

James Kent worked for many years within the acute sector of the NHS, most recently as Clinical Lead Pharmacist and later Chief Pharmacist at Southend Hospital NHS Trust. From 2011-2017 he was also seconded to an organisation called PrescQIPP as the Secondary Care  Lead. This organisation seeks to...

Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001). Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on...

John leads Amgen’s Biologic Discovery function responsible for identifying large molecule therapeutic candidates in collaboration with all Amgen Therapeutic Areas, including the discovery of fully human antibody therapeutics using the company’s proprietary platform technology. John joined Amgen in...

Dr. Emma Dean is a Director Physician specialising in Early Clinical Drug Development and joined AstraZeneca in April 2017. Prior to this, she was medical lead of the Experimental Cancer Medicine Team at The Christie NHS Foundation Trust and The University of Manchester, leading the unit through...

Jonathan has a phD in cellular and molecular biology from the university of Strasbourg. After a postdoctoral at the Ludwig Institute for Cancer Research (Lausanne Branch) in innate immunity, Jonathan joined Glenmark Pharmaceuticals in 2010 as senior research Officer. He holds now a position of...

Dr. Tchistiakova is currently Senior Director at BioMedicine Design (BMD) department of Pfizer leading multifunctional group focused on the discovery of human therapeutic antibodies, antibody humanization, optimization and biotherapeutic formats engineering including bi-, tri-specifics and T cell...

Dr. Joseph Eid is a physician, board certified in Medical Oncology, Hematology, and Internal Medicine. He joined BMS in 2017 as Senior Vice President and Head of Medical. Before joining BMS, Joe worked at Merck in Oncology Clinical Research, and in this capacity he was the team leader for...

Business Operations and Alliance Management for the BBU as well as be the Chief of Staff for the leadership team. Ian brings nearly 20 years of experience in the pharmaceutical industry. Prior to joining Biogen, Ian was at The Medicines Company for more than six years where his most recent role was ...

Pinal Patel is a Strategic Recruitment – Oncology Lead within Global Clinical Operations at Bristol-Myers Squibb. Prior to joining Bristol-Myers Squibb, she was a Study Coordinator at Yale University, School of Medicine Psychiatry working on implementing clinical trials for the Neuroscience...

Karin Jooss serves as Chief Scientific Officer of Gritstone Oncology.  Dr. Jooss joined Gritstone from Pfizer, where she served as head of Cancer Immunotherapeutics within the Vaccine Immunotherapeutics department for seven years.  While at Pfizer, she built and led immuno-oncology teams, was a...

Sascha Mundstein (Harvard, INSEAD) is a digital engineer and emerging technology expert at Pfizer, where he has helped transform innovative ideas into solutions that benefit patients directly. In recent years, he has been focusing on mobile technologies, health data collection through sensors and...

Dr. Marjorie Shapiro received her Ph.D. in immunology from the University of  Pennsylvania where she studied molecular mechanisms underlying antibody diversity.  She has over 25 years experience regulating CMC for monoclonal antibodies and related products, including antibody-drug...

Lothar Germeroth is Senior Vice President at Juno Inc. and Managing Director at Juno Therapeutics GmbH, and joined Juno through the acquisition of Stage Cell Therapeutics in May 2015. Dr. Germeroth has over 25 years of management experience in biotechnology. Dr. Germeroth served as the CEO at IBA...

Michael Streit, MD serves as Senior Director and Clinical Research Leader in the Oncology Translational Medicine and Early Development Department at Janssen. He is responsible for the clinical development of a novel agonistic anti-CD40 antibody and involved in the management of an emerging...

M. Anthony Moody is Associate Professor in the Department of Pediatrics, Division of Infectious Diseases at Duke University Medical Center and the Chief Medical Officer at the Duke Human Vaccine Institute. Dr. Moody obtained his MD from Duke University School of Medicine in 1999 after which he...

Dr. Matthew Hewitt has held roles in research and development over the past 10 years in both academia and industry. Over that time he has built and run successful programs in pre-clinical, IND-enabling, and clinical support settings using his extensive immunology and molecular biology...

Patrick Burke is an Associate Director in the Chemistry department at Seattle Genetics where his research is focused on the discovery and implementation of new payload and linker technologies for antibody-drug conjugates.  Prior to his 12 years at Seattle Genetics, he did post-doctoral research in...

Paul Carter is a Senior Director and Staff Scientist in the Antibody Engineering Department at Genentech, Inc. His research interests focus on creating new antibody technologies and applying them to develop future generations of antibody therapeutics.   Carter has published more than 110 scientific ...

BA diploma with focus on Production and Logistics from the University of Augsburg 3 Years Demand and Forecasting at Fujitsu Siemens Computer5 Years “Seihan” (fully integrated supply chain) Manager at Alpine Electronics7 Years Supply Chain Manager at Teva / Mepha Switzerland Since 2014 Head of...

Professional BackgroundPascal Touchon is Senior Vice President, Global Head Cell & Gene and member of the Oncology Executive Committee. In this role, Pascal is responsible for leading a cross- functional and cross-divisional team in Cell & Gene Therapies, reporting to Elizabeth Barrett, CEO ...

With over 15 years of experience in Occupational Health and Safety, Chris has held roles in both Manufacturing and Research and Development Organizations.  Chris’ skill set as a Toxicologist facilitates his understanding of Potent Materials and the necessity to handle these materials with the...

Recognized as Global Life Sciences Executive, key opinion leader in clinical operations, patient engagement and real world data, Mimi has brought together international disease area leaders and drug agencies from around the global to improve patient care. Mimi's aim in life is to touch and to...

Establishing clinical development strategy from the pre-IND setting to pivotal trials and registration with focus on biosimilars of insulin and insulin analogues.Successfully performed several clinical trials including hyperinsulinemic euglycemic clamps and bioequivalence, Phase III...

Per-Ola Freskgard is currently a vice Director and Expert Scientist in Neuroscience, Roche Innovation Center Basel, Pharma Research and Early Development (pRED) ROCHE. He has a Ph.D. in Biochemistry and a post-doctoral visiting associate at California Institute of Technology, Chemical...

Project manager of the International Clinical Trials Registry Platform (ICTRP) in the World Health Organization since 2011, expert in clinical trials database design, clinical trials registration & results and ethics committees information systems. Member of several international working groups ...

Divya Chadha Manek is the Head of BusinessDevelopment (Commercial) for the NIHR ClinicalResearch Network (CRN). Divya’s role is tomaintain strategic relationships with Global andUK life sciences companies. Divya facilitates keydiscussions between life sciences industry andthe Clinical Research...

After graduating, Jeff Parry spent 5 years as an industrial hygienist before joining Astrazeneca as a First Line Manager in the Tablets Pilot Plant at Macclesfield. During the following 18 years, he has worked within various Astrazeneca pilot plants producing both sterile parenteral, and oral solid ...

Roland Kontermann holds a PhD in Molecular Biology from the University of Heidelberg. After working as a postdoc in the laboratory of Sir Gregory Winter at the MRC Centre for Protein Engineering, Cambridge, UK, group leader at the Institute of Molecular Biology and Tumor Biology of the University...

Tom Nittoli has over 20 years of experience in the pharmaceutical industry and is currently Director of R&D Chemistry.  Dr. Nittoli joined Regeneron in 2010 to advance conjugated antibodies and proteins from discovery to development.  Since joining Regeneron, he has developed a variety of small ...

Dr. Serafino Pantano has several years of experience in Translational Science, Biomarkers and Diagnostics, and he is currently Biomarker and Diagnostics Leader for the EMEAC region in Merck, Sharp & Dohme (MSD), in Lucerne, Switzerland.  Dr. Pantano received his PhD in Human Morphological...

Ivana is a certified MD who has spent over a decade in clinical research, gaining experience in various country, regional and global job roles at MSD. She holds a position of Global Operations Lead – Agreements, as well as the process ownership over site ready support with an accent on the...

William F. Dall'Acqua, Ph.D. is VP, Research and Development at MedImmune, a biopharmaceutical company headquartered in Gaithersburg, Maryland.  Dr. Dall'Acqua has been studying protein structure, function and engineering for over twenty years and has co-authored over sixty papers and one...

Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Shane was Director of Research at Fusion Antibodies Ltd where he was responsible for the discovery and development of multiple drug...

Jan Pieter Kappelle is Senior Director, Global Clinical Trial Supplies at UCB, the world leading global epilepsy company Inspired by Patients and Driven by Science. In his role he holds responsibilities for coordinating global supplies for UCB sponsored clinical trials including supply chain...

Dr. Li is a Senior Director of Clinical Pharmacology at Shire.  She has nearly 20 years of industrial experience in clinical development for small molecules, RNA based therapies and biologics, including monoclonal antibodies and enzyme replacement therapies.  Prior to joining Shire in June...

Dr. Boon received his Ph.D. in Biochemistry at the University of Amsterdam. In 2003 he was one of the founders of Bioceros BV were he currently hold a position of CSO. In addition, he held position as CSO for 4AZA Bioscience NV, FF Pharma and VP Preclinical for PanGenetics BV and Tanox. Dr. Boon is ...

An innovation award winning operational strategy expert, blockchain advocate and patient engagement thought leader with over 17 years in the NHS on commission by the DOH and in Industry (Hoffman La-Roche, Amgen, ALMAC, ICON and Biogen). An R&D transformation change champion. Currently part of...